Abeona Therapeutics (ABEO) Competitors $4.85 -0.07 (-1.42%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABEO vs. DYN, HROW, GPCR, ETNB, CMRX, CDMO, RCUS, MLYS, PAHC, and SYREShould you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Dyne Therapeutics (DYN), Harrow (HROW), Structure Therapeutics (GPCR), 89bio (ETNB), Chimerix (CMRX), Avid Bioservices (CDMO), Arcus Biosciences (RCUS), Mineralys Therapeutics (MLYS), Phibro Animal Health (PAHC), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical preparations" industry. Abeona Therapeutics vs. Dyne Therapeutics Harrow Structure Therapeutics 89bio Chimerix Avid Bioservices Arcus Biosciences Mineralys Therapeutics Phibro Animal Health Spyre Therapeutics Abeona Therapeutics (NASDAQ:ABEO) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations. Is ABEO or DYN more profitable? Dyne Therapeutics' return on equity of -57.46% beat Abeona Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Abeona TherapeuticsN/A -203.27% -64.56% Dyne Therapeutics N/A -57.46%-51.62% Do analysts rate ABEO or DYN? Abeona Therapeutics presently has a consensus target price of $17.50, suggesting a potential upside of 260.82%. Dyne Therapeutics has a consensus target price of $47.46, suggesting a potential upside of 506.15%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dyne Therapeutics is more favorable than Abeona Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.07 Which has more volatility and risk, ABEO or DYN? Abeona Therapeutics has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Does the MarketBeat Community prefer ABEO or DYN? Abeona Therapeutics received 481 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 77.19% of users gave Dyne Therapeutics an outperform vote while only 69.35% of users gave Abeona Therapeutics an outperform vote. CompanyUnderperformOutperformAbeona TherapeuticsOutperform Votes52569.35% Underperform Votes23230.65% Dyne TherapeuticsOutperform Votes4477.19% Underperform Votes1322.81% Does the media refer more to ABEO or DYN? In the previous week, Dyne Therapeutics had 5 more articles in the media than Abeona Therapeutics. MarketBeat recorded 9 mentions for Dyne Therapeutics and 4 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 1.04 beat Dyne Therapeutics' score of 0.87 indicating that Abeona Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in ABEO or DYN? 80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 5.4% of Abeona Therapeutics shares are owned by company insiders. Comparatively, 20.8% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has stronger valuation and earnings, ABEO or DYN? Abeona Therapeutics has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbeona Therapeutics$3.50M67.25-$54.19M-$2.19-2.21Dyne TherapeuticsN/AN/A-$235.94M-$3.35-2.34 SummaryDyne Therapeutics beats Abeona Therapeutics on 10 of the 17 factors compared between the two stocks. Remove Ads Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABEO vs. The Competition Export to ExcelMetricAbeona TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$235.39M$6.25B$5.28B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-1.806.6921.6317.68Price / Sales67.25222.70371.0992.89Price / CashN/A65.6738.1534.64Price / Book8.085.776.373.94Net Income-$54.19M$142.01M$3.20B$247.45M7 Day Performance10.98%2.88%1.79%0.48%1 Month Performance-8.32%-13.93%-9.41%-7.08%1 Year Performance-37.50%-12.36%9.61%-0.35% Abeona Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABEOAbeona Therapeutics4.1864 of 5 stars$4.85-1.4%$17.50+260.8%-35.6%$235.39M$3.50M-1.80N/APositive NewsDYNDyne Therapeutics3.5776 of 5 stars$7.49-9.5%$47.46+533.7%-69.1%$847.28MN/A-2.10100HROWHarrow2.5909 of 5 stars$23.09-1.8%$60.50+162.0%+92.6%$823.25M$199.61M-24.56182Positive NewsGPCRStructure Therapeutics2.5837 of 5 stars$14.31-5.4%$81.29+468.0%-49.8%$820.58MN/A-19.34136News CoverageETNB89bio2.5898 of 5 stars$5.49-4.9%$27.56+401.9%-36.2%$801.45MN/A-1.8940Short Interest ↑High Trading VolumeCMRXChimerix2.7397 of 5 stars$8.52-0.1%$8.53+0.2%+834.8%$799.21M$212,000.00-9.0690Analyst ForecastPositive NewsCDMOAvid Bioservices0.8042 of 5 stars$12.50+0.1%$12.25-2.0%+83.8%$799.18M$139.91M-5.23320Upcoming EarningsHigh Trading VolumeRCUSArcus Biosciences2.2837 of 5 stars$7.28+5.9%$30.25+315.8%-50.9%$764.88M$258M-2.31500Gap DownHigh Trading VolumeMLYSMineralys Therapeutics2.3683 of 5 stars$12.05-2.8%$33.00+173.9%+12.5%$756.56MN/A-3.3128Insider TradeShort Interest ↑High Trading VolumePAHCPhibro Animal Health3.8202 of 5 stars$18.66-2.8%$21.00+12.5%+27.3%$755.79M$1.11B38.881,860News CoveragePositive NewsGap DownSYRESpyre Therapeutics1.6655 of 5 stars$12.39-3.1%$50.33+306.2%-65.8%$746.58M$890,000.00-1.66100Gap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Dyne Therapeutics Alternatives Harrow Alternatives Structure Therapeutics Alternatives 89bio Alternatives Chimerix Alternatives Avid Bioservices Alternatives Arcus Biosciences Alternatives Mineralys Therapeutics Alternatives Phibro Animal Health Alternatives Spyre Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABEO) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ABEO Stock Free ABEO Stock Alerts